1. Home
  2. RVMDW vs VCEL Comparison

RVMDW vs VCEL Comparison

Compare RVMDW & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVMDW
  • VCEL
  • Stock Information
  • Founded
  • RVMDW 2014
  • VCEL 1989
  • Country
  • RVMDW United States
  • VCEL United States
  • Employees
  • RVMDW N/A
  • VCEL N/A
  • Industry
  • RVMDW
  • VCEL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RVMDW
  • VCEL Health Care
  • Exchange
  • RVMDW Nasdaq
  • VCEL Nasdaq
  • Market Cap
  • RVMDW N/A
  • VCEL N/A
  • IPO Year
  • RVMDW N/A
  • VCEL 1997
  • Fundamental
  • Price
  • RVMDW $0.10
  • VCEL $57.09
  • Analyst Decision
  • RVMDW
  • VCEL Strong Buy
  • Analyst Count
  • RVMDW 0
  • VCEL 7
  • Target Price
  • RVMDW N/A
  • VCEL $63.29
  • AVG Volume (30 Days)
  • RVMDW 15.6K
  • VCEL 346.3K
  • Earning Date
  • RVMDW 02-26-2025
  • VCEL 02-27-2025
  • Dividend Yield
  • RVMDW N/A
  • VCEL N/A
  • EPS Growth
  • RVMDW N/A
  • VCEL N/A
  • EPS
  • RVMDW N/A
  • VCEL 0.07
  • Revenue
  • RVMDW $742,000.00
  • VCEL $226,844,000.00
  • Revenue This Year
  • RVMDW N/A
  • VCEL $23.08
  • Revenue Next Year
  • RVMDW N/A
  • VCEL $21.58
  • P/E Ratio
  • RVMDW N/A
  • VCEL $794.21
  • Revenue Growth
  • RVMDW N/A
  • VCEL 22.48
  • 52 Week Low
  • RVMDW $0.10
  • VCEL $39.12
  • 52 Week High
  • RVMDW $0.12
  • VCEL $63.00
  • Technical
  • Relative Strength Index (RSI)
  • RVMDW N/A
  • VCEL 46.07
  • Support Level
  • RVMDW N/A
  • VCEL $54.45
  • Resistance Level
  • RVMDW N/A
  • VCEL $63.00
  • Average True Range (ATR)
  • RVMDW 0.00
  • VCEL 2.17
  • MACD
  • RVMDW 0.00
  • VCEL -0.41
  • Stochastic Oscillator
  • RVMDW 0.00
  • VCEL 30.88

About RVMDW Revolution Medicines Inc. Warrant

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products includes RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs.

Share on Social Networks: